

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INTAS PHARMACEUTICALS LTD.,
Petitioner,

v.

ATOSSA THERAPEUTICS, INC.,
Patent Owner

Case PGR2025-00043
Patent 12,071,391

PATENT OWNER'S MOTION TO SEAL

I. Introduction

Pursuant to the default protective order and 37 C.F.R. §§ 42.14, 42.54, and 42.55, Patent Owner Atossa Therapeutics, Inc. (“Atossa”) hereby moves to seal its Motion for Additional Discovery (the “Additional Discovery Motion”). Atossa previously sought to seal Atossa’s Brief in Support of Discretionary Denial (the “Discretionary Brief”) and Exhibit 2015 (“Intas Requirements for Resolving Disputes with Atossa”). Pap.6. That motion is pending. The present motion to seal relates to information that was the subject of the previous motion to seal (EX2015) on the basis that it is non-public business information.

II. Good Cause Exists to Seal the Discretionary Brief and EX2015

Pursuant to the default protective order (filed by Atossa as Exhibit 2016) and 37 C.F.R. §§ 42.14, 42.54 and 42.55, Atossa moves to seal its Additional Discovery Motion submitted with this motion.

“Good cause” exists to seal the Additional Discovery Motion because the document reflects details of EX2015 and therefore includes material that Atossa represents is non-public business information. *See Celltrion, Inc. v. Genentech, Inc.*, IPR2016-01667, Pap.31, 4 (July 23, 2018); *Greene’s Energy Grp., LLC v. Oil States Energy Servs., LLC*, IPR2014-00216, Pap.27, 5 (Sept. 23, 2014); 37 C.F.R. § 42.54. Atossa itself intended the details of the settlement discussions to be maintained as confidential as explained in Atossa’s previous motion to seal the

Discretionary Brief. Atossa's Additional Discovery Motion contains information related to settlement discussions and likewise should remain confidential.

Atossa has filed and served on Intas an unredacted, nonpublic version of the corresponding Additional Discovery Motion with this motion.

III. Conclusion

For the foregoing reasons, Atossa respectfully requests that the Board grant this motion to seal.

Respectfully submitted by:

Dated: December 8, 2025

/s/ Megan Raymond

Megan Raymond (Reg. No. 72,997)

J. Steven Baughman (Reg. No. 47,414)

*Attorneys For Patent Owner
Atossa Therapeutics, Inc.*

CERTIFICATE OF PAGE COUNT

The undersigned certifies that the foregoing PATENT OWNER'S MOTION TO SEAL complies with the 15-page limitation in 37 C.F.R. §42.24(a)(1)(v).

Dated: December 8, 2025

Respectfully Submitted,

By: /s/ Megan Raymond
Megan Raymond (Reg. No. 72,997)
GROOMBRIDGE, WU, BAUGHMAN &
STONE LLP
801 17th Street, NW, Suite 1050
Washington, DC, 20006
P: (202)-505-5878
megan.raymond@groombridgewu.com

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of **PATENT OWNER'S MOTION TO SEAL** has been served in its entirety by causing the aforementioned document to be electronically mailed to the following attorneys of record for the Petitioner listed below:

Alejandro Menchaca
Ben J. Mahon
Amanda C. Jackson
151IPR@mcandrews-ip.com

Dated: December 8, 2025

Respectfully submitted,

By: /Sayem Osman/
Sayem Osman